Disease-modifying therapies for MS
Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
These drugs do not repair damage already done. They reduce how often new damage happens, which is why starting before damage accumulates matters more than which drug is chosen later.
The field has moved away from starting with the mildest option and escalating. Starting with a highly effective treatment early is now widely favoured, and the trade-off is a different and more serious risk profile.
Related pages: Multiple sclerosis (MS)
The bottom line
- Disease-modifying therapies reduce relapse rate and new MRI lesions.
- Higher-efficacy treatments work better and carry greater risks.
- They are mainly effective in relapsing MS; options in progressive MS are more limited.
- Treatment is monitored with regular MRI and blood tests.
- How long treatment should continue, and whether it can safely be stopped with age.
- How to treat the progressive component, which no current drug clearly halts.
The story, step by step
- 1. The strategy ()
- 2. Antibody infusions ()
- 3. Oral drugs ()
- 4. The older injectables ()
- 5. Practical questions ()
What the evidence labels mean
Early and effective
What happens
The biggest change in MS care is not a drug but a timing decision.
What the research shows
- The older approach started with a safe, moderately effective injectable and escalated only after failure, which meant accumulating damage before switching.
- Evidence now favours starting a highly effective treatment early, with better long-term disability outcomes in observational comparisons.
- The goal often used is no evidence of disease activity: no relapses, no new or enlarging MRI lesions, and no disability worsening.
- It is a useful target rather than a guarantee, since quiet nerve loss can continue even when all three measures look clean.
- Nerve fibres lost are not recovered, which is the whole argument for acting before the damage rather than after it.
Why it matters
If a diagnosis has just been made, asking about early high-efficacy treatment and why a particular drug is being proposed is a reasonable conversation to have.
What's still uncertain
- Head-to-head trials of early intensive versus escalation strategies are still reporting.
Read more
- NINDS: Multiple SclerosisGovernment
- National Multiple Sclerosis SocietyNonprofit
Next: Antibody infusions
The high-efficacy group
What happens
Monoclonal antibodies given by infusion or injection, which are the most effective available.
What the research shows
- Anti-CD20 drugs (ocrelizumab, ofatumumab, ublituximab, and rituximab used off-label) deplete B cells. Ocrelizumab is also approved for primary progressive MS. Risks include infusion reactions, lower antibody levels over time, and more infections.
- Natalizumab blocks immune cells from crossing into the brain and is highly effective. It carries a risk of progressive multifocal leukoencephalopathy, a serious brain infection, which is why JC virus antibody status is tested before and during treatment.
- PML risk rises with positive JC virus antibodies, higher antibody levels, longer treatment and previous immunosuppression. People who are JC virus negative are retested regularly.
- Alemtuzumab is given as short courses that reset the immune system, with lasting effect, but carries a substantial risk of later autoimmune conditions, particularly thyroid disease and a serious platelet disorder, requiring monthly monitoring for years.
- Stopping natalizumab abruptly can cause a severe return of disease activity, so switching is planned carefully.
Why it matters
These are the most effective drugs and the ones with the most serious specific risks. The monitoring is not optional, and it is a reason to keep appointments even when well.
What's still uncertain
- How best to sequence these therapies, and when to de-escalate, is not settled.
Read more
- FDA: Natalizumab (Tysabri) and progressive multifocal leukoencephalopathyGovernment
- National Multiple Sclerosis SocietyNonprofit
Next: Oral drugs
Tablets and capsules
What happens
Several oral options sit between the injectables and the antibody infusions in effectiveness.
What the research shows
- S1P receptor modulators (fingolimod, siponimod, ozanimod, ponesimod) trap lymphocytes in lymph nodes. First doses may need heart rhythm monitoring, and they require eye checks for macular oedema and can reactivate shingles. Siponimod is licensed for active secondary progressive MS.
- Stopping an S1P drug can be followed by severe rebound disease activity, so they are not stopped abruptly.
- Fumarates (dimethyl fumarate, diroximel fumarate) commonly cause flushing and stomach upset early on, and require white cell monitoring because of a small PML risk when counts fall.
- Teriflunomide is taken daily and requires liver monitoring. It persists in the body for a long time and can cause birth defects, so it must not be taken in pregnancy and an accelerated elimination procedure exists.
- Cladribine is given as short courses over two years with a lasting effect, and requires blood count monitoring and infection screening.
Why it matters
Convenience is not the only consideration: each of these has its own monitoring requirement, and skipping blood tests is the main avoidable risk.
What's still uncertain
- Long-term safety data are shorter for the newer oral agents.
Read more
- NINDS: Multiple SclerosisGovernment
- National Multiple Sclerosis SocietyNonprofit
Next: The older injectables
Interferons and glatiramer
What happens
The first generation of MS treatments, still used in specific situations.
What the research shows
- Interferon beta and glatiramer acetate are given by injection, from several times a week to every two weeks depending on the formulation.
- They reduce relapse rate by roughly a third, considerably less than the high-efficacy options.
- Their advantage is a long safety record with no serious cumulative risks and no immune suppression.
- Interferons cause flu-like symptoms after injection, which usually ease with time and can be managed; they require liver and blood count monitoring. Glatiramer causes injection site reactions and occasionally a brief alarming flushing and chest tightness reaction that is harmless.
- They remain reasonable for mild disease and are among the options with the most reassuring data around pregnancy.
Why it matters
These are not obsolete, but they are no longer the default starting point for someone with active disease.
What's still uncertain
- How to weigh their safety advantage against lower efficacy is an individual decision.
Read more
- NINDS: Multiple SclerosisGovernment
- National Multiple Sclerosis SocietyNonprofit
Next: Practical questions
Pregnancy, vaccines and monitoring
What happens
The issues that come up most often once treatment has started.
What the research shows
- Pregnancy: MS itself does not reduce fertility, and relapse rates typically fall during pregnancy and rise in the months after delivery. Several drugs must be stopped beforehand, and some must be stopped well in advance. This is a planned conversation, not a last-minute one.
- Breastfeeding is possible on some treatments and not others, and exclusive breastfeeding may reduce early postpartum relapses.
- Vaccines: live vaccines are generally avoided on immunosuppressive treatment, and vaccination is best completed before starting. Responses to some vaccines are reduced on anti-CD20 drugs.
- Monitoring: regular blood tests and MRI scans continue even when a person feels well, because new lesions often cause no symptoms and are the earliest sign treatment is not working.
- Vitamin D is commonly supplemented in MS, since low levels are associated with higher risk and activity. Trials of supplementation have not shown a clear effect on the course of established disease, so it is reasonable rather than a treatment.
- Stopping treatment: some people over a certain age with long-standing stable disease consider stopping, and trials of this are ongoing. Stopping some drugs risks rebound activity and is never done without advice.
Why it matters
Anyone with MS who may want a pregnancy should raise it early, because the choice of drug now affects the options later.
What's still uncertain
- Whether and when treatment can be safely stopped with age is an active research question.
Read more
More plain-language reading
- OwieClear: Managing an MS relapseOwieClear
- OwieClear: The four patterns of MSOwieClear
- OwieClear: Treating the symptoms of MSOwieClear